Comparison of visual outcomes of two trifocal IOLs

Abstract

PURPOSE:To compare the visual outcomes of bilateral im-plantation of two commercially available trifocal intraocular lenses (IOLs) (AcrySof IQ PanOptix IOL; Alcon Laboratories, Inc and AcrivaUD Trinova IOL; VSY Biotechnology). METHODS:This comparative, investigator-initiated, single-center randomized trial was conducted by the Department of Ophthal-mology of the Medipol Mega University Hospital in Istanbul, Tur-key. Adult patients were randomized in a 1:1 ratio using a block randomization program to undergo cataract surgery and receive the implantation of either the PanOptix or Trinova IOL in both eyes. Outcome measures including binocular uncorrected and cor-rected visual acuities at distance, intermediate (66 cm), and near (40 cm), defocus curve, refractive outcomes, contrast sensitivity, glare and halos, and patient satisfaction were assessed at a mini-mum of 3 months following bilateral IOL implantation. RESULTS:A total of 71 patients (142 eyes) were included, with 35 patients (70 eyes) in the PanOptix IOL group and 36 patients (72 eyes) in the Trinova IOL group. At the 3-month follow-up examination, mean distance-corrected intermedi-ate visual acuity (primary endpoint) was significantly better for the PanOptix IOL group (0.0 & PLUSMN; 0.09 logMAR) compared with the Trinova IOL group (0.01 & PLUSMN; 0.10 logMAR) (P = .0304). Mean logMAR uncorrected intermediate acuity (UIVA) and near (UNVA) visual acuity were also significantly better for the PanOptix IOL group (UIVA = 0.1 & PLUSMN; 0.10 logMAR; UNVA= 0.0 & PLUSMN; 0.09 logMAR) compared with the Trinova IOL group (UIVA = 0.2 & PLUSMN; 0.10 logMAR; UNVA = 0.2 & PLUSMN; 0.11 logMAR) (both P < .001). There were no statistically significant differences in all other outcomes between groups. No adverse events were reported in both groups. CONCLUSIONS:These results suggest that the PanOptix IOL provides better intermediate and near visual outcomes com-pared to the Trinova IOL and represents a good choice for pa-tients seeking to achieve spectacle independence.